Co-cultured with MSCs, CML cells reduce caspase-3 activation and modulate Bcl-XL (anti-apoptotic protein) expression after treatment with imatinib which signify MSC-mediated protection of CML cells [91, 92]. This evidence concerns the gene BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive.